An updated analysis of JULIET, a global pivotal phase 2 trial of tisagenlecleucel in adult patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL)
暂无分享，去创建一个
G. Salles | U. Jaeger | H. Holte | C. Tam | S. Schuster | J. Westin | E. Waller | P. Borchmann | S. Jaglowski | C. Andreadis | I. Fleury | S. Mielke | L. Pacaud | R. Awasthi | R. Maziarz | S. R. Foley | S. Agoulnik | O. Anak | F. Tai | Bishop | C. D. Corral | P. Ho | J. Mcguirk